SC 13G: A statement of beneficial ownership of common stock by certain persons Post author:andrewkaretas Post published:November 4, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue ReadingSC 13G: A statement of beneficial ownership of common stock by certain persons
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:October 23, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
SC 13G/A: An amendment to the SC 13G filing Post author:andrewkaretas Post published:October 22, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue ReadingSC 13G/A: An amendment to the SC 13G filing
144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing Post author:andrewkaretas Post published:October 21, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing
8-K: Report of unscheduled material events or corporate event Post author:andrewkaretas Post published:October 7, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading8-K: Report of unscheduled material events or corporate event
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:August 23, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing Post author:andrewkaretas Post published:August 21, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing
10-Q: Quarterly report which provides a continuing view of a company’s financial position Post author:andrewkaretas Post published:August 7, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading10-Q: Quarterly report which provides a continuing view of a company’s financial position
8-K: Report of unscheduled material events or corporate event Post author:andrewkaretas Post published:August 7, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading8-K: Report of unscheduled material events or corporate event
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 20, 2024 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
